Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 6519704, 9 pages
https://doi.org/10.1155/2017/6519704
Research Article

Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease

1Servicio de Medicina Interna, UMAE Hospital de Especialidades, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
2Servicio de Urgencias, H.G.R. No. 1 “Dr. Carlos Mac Gregor Sánchez Navarro”, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
3Servicio de Neurología, UMAE Hospital de Especialidades, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
4Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
5Unidad de Investigación en Nutrición Médica, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
6Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, H.G.R. No. 1 “Dr. Carlos Mac Gregor Sánchez Navarro”, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
7Unidad de Investigación Médica en Medicina Reproductiva, UMAE H.G.O. No. 4, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico

Correspondence should be addressed to Irma Isordia-Salas; moc.liamg@6102.osiamri

Received 13 October 2016; Accepted 13 December 2016; Published 8 February 2017

Academic Editor: Stefano de Franciscis

Copyright © 2017 Elsa Aburto-Mejía et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. W. F. Wilson, W. B. Kannel, H. Silbershatz, and R. B. D'Agostino, “Clustering of metabolic factors and coronary heart disease,” Archives of Internal Medicine, vol. 159, no. 10, pp. 1104–1109, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. H. P. Kohler and P. J. Grant, “Plasminogen-activator inhibitor type 1 and coronary artery disease,” New England Journal of Medicine, vol. 342, no. 24, pp. 1792–1801, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. B. E. Sobel, “Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox,” Circulation, vol. 99, no. 19, pp. 2496–2498, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M.-C. Alessi and I. Juhan-Vague, “PAI-1 and the metabolic syndrome: links, causes, and consequences,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2200–2207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. B. E. K. Klein, R. Klein, and K. E. Lee, “Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam,” Diabetes Care, vol. 25, no. 10, pp. 1790–1794, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Koren-Morag, U. Goldbourt, and D. Tanne, “Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease,” Stroke, vol. 36, no. 7, pp. 1366–1371, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Rojas, C. A. Aguilar-Salinas, A. Jiménez-Corona et al., “Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006,” Salud Pública de México, vol. 52, supplement 1, pp. S11–S18, 2010. View at Google Scholar
  8. I. Isordia-Salas, D. Santiago-Germán, H. Rodrìguez-Navarro et al., “Prevalence of metabolic syndrome components in an urban mexican sample: comparison between two classifications,” Experimental Diabetes Research, vol. 2012, Article ID 202540, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Miller, A. Alcaraz Ruiz, G. Borrayo Sánchez, E. Almeida Gutiérrez, R. M. Vargas Guzmán, and R. Jáuregui Aguilar, “Metabolic syndrome: clinical and angiographic impact on patients with acute coronary syndrome,” Cirugia y Cirujanos, vol. 78, no. 2, pp. 113–120, 2010. View at Google Scholar · View at Scopus
  10. L. Badimon, R. Hernández-Vera, and G. Vilahur, “Determinants of cardiovascular risk in diabetes beyond hyperglycemia,” Journal of Cardiovascular Disease, vol. 1, no. 2, pp. 53–62, 2013. View at Google Scholar
  11. I. J. Kullo, G. T. Gau, and A. Jamil Tajik, “Novel risk factors for atherosclerosis,” Mayo Clinic Proceedings, vol. 75, no. 4, pp. 369–380, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Isordia-Salas, A. Leaños-Miranda, I. M. Sainz, E. Reyes-Maldonado, and G. Borrayo-Sánchez, “Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients,” Revista Espanola de Cardiologia, vol. 62, no. 4, pp. 365–372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Esparza-García, D. Santiago-Germán, M. Guadalupe Valades-Mejía et al., “GLU298ASP and 4G/5G polymorphisms and the risk of ischemic stroke in young individuals,” The Canadian Journal of Neurological Sciences, vol. 42, no. 5, pp. 310–316, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Festa, R. D'Agostino Jr., S. S. Rich et al., “Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study,” Circulation, vol. 107, no. 19, pp. 2422–2427, 2003. View at Publisher · View at Google Scholar
  15. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “The metabolic syndrome—a new worldwide definition,” Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 35, supplement 1, pp. S64–S71, 2011. View at Publisher · View at Google Scholar
  17. M. Margaglione, E. Grandone, G. Cappucci et al., “An alternative method for PAI-1 promoter polymorphism (4G/5G) typing,” Thrombosis and haemostasis, vol. 77, no. 3, pp. 605–606, 1997. View at Google Scholar · View at Scopus
  18. C. Lubrano, G. Valacchi, P. Specchia et al., “Integrated Haematological Profiles of Redox Status, Lipid, and Inflammatory Protein Biomarkers in Benign Obesity and Unhealthy Obesity with Metabolic Syndrome,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 490613, 14 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. C. S. Coffey, F. W. Asselbergs, P. R. Hebert et al., “The association of the metabolic syndrome with PAI-1 and t-PA levels,” Cardiology Research and Practice, vol. 2011, Article ID 541467, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Fernández-Bergés, L. Consuegra-Sánchez, J. Peñafiel et al., “Metabolic and inflammatory profiles of biomarkers in obesity, metabolic syndrome, and diabetes in a mediterranean population. DARIOS inflammatory study,” Revista Espanola de Cardiologia, vol. 67, no. 8, pp. 624–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Al-Hamodi, I. S. Ismail, R. Saif-Ali, K. A. Ahmed, and S. Muniandy, “Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects,” Cardiovascular Diabetology, vol. 10, article 23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Undas, K. E. Brummel-Ziedins, and K. G. Mann, “Anticoagulant effects of statins and their clinical implications,” Thrombosis and Haemostasis, vol. 111, no. 3, pp. 392–400, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Cesari, S. B. Kritchevsky, H. H. Atkinson et al., “Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study,” American Heart Journal, vol. 157, no. 2, pp. 334.e1–334.e8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Kagami, T. Kuhara, K. Okada, Y. Kuroda, W. A. Border, and N. A. Noble, “Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells,” Kidney International, vol. 51, no. 3, pp. 664–671, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Saremi, D. C. Schwenke, T. A. Buchanan et al., “Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, pp. 393–399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Zhang, N. A. Noble, W. A. Border, R. T. Owens, and Y. Huang, “Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells,” American Journal of Physiology—Endocrinology and Metabolism, vol. 295, no. 4, pp. E810–E819, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. B. M. Egan, J. Li, S. Qanungo, and T. E. Wolfman, “Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988–2010,” Circulation, vol. 128, no. 1, pp. 29–41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ruiz-Quezada, M. Vázquez-Del Mercado, I. Parra-Rojas et al., “Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters,” Annales de Genetique, vol. 47, no. 2, pp. 155–162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. U. De La Cruz-Mosso, J. F. Muñoz-Valle, A. B. Salgado-Bernabé et al., “Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children,” Jornal de Pediatria, vol. 89, no. 5, pp. 492–498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. N. H. Naran, N. Chetty, and N. J. Crowther, “The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity,” Atherosclerosis, vol. 196, no. 1, pp. 155–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. Martínez-Calatrava, M. T. Martínez-Larrad, C. Zabena, J. L. González-Sánchez, C. Fernández-Pérez, and M. Serrano-Ríos, “The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population,” Diabetes, Obesity and Metabolism, vol. 9, no. 1, pp. 134–135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Kathiresan, S. B. Gabriel, Q. Yang et al., “Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels,” Circulation, vol. 112, no. 12, pp. 1728–1735, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Margaglione, G. Cappucci, M. d’Addedda et al., “PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 4, pp. 562–567, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. P. E. Morange, N. Saut, M. C. Alessi et al., “Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: The HIFMECH Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 10, pp. 2250–2257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Isordia-Salas, M. E. Galván-Plata, A. Leaños-Miranda et al., “Proinflammatory and prothrombotic state in subjects with different glucose tolerance status before cardiovascular disease,” Journal of Diabetes Research, vol. 2014, Article ID 631902, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus